中生制药(01177.HK)两款乙肝新药获纳入突破性治疗药物程序

阿斯达克财经
Yesterday

中生制药(01177.HK) 公布,附属公司正大天晴自主研发的国家1类创新药TQ-A3334(Toll样受体7激动剂)及TQA3605(核心蛋白变构调节剂),均已获国家药监局药品审评中心(CDE)纳入突破性治疗药物程序。两款创新药分别针对慢性乙型肝炎治疗中尚未满足的功能性治愈与低病毒血症(LLV)两大需求。其中TQ-A3334为口服高选择性TLR7激动剂,是次获纳入突破性治疗药物程序,主要基于其...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10